Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) is now available.
Jubilant Pharmova Limited announced the successful completion of a USFDA pharmacovigilance inspection at its subsidiary, Jubilant Cadista Pharmaceuticals Inc., with no observations. This outcome underscores the company’s commitment to high standards of quality, safety, and compliance, reinforcing its strong position in the pharmaceutical industry.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited is a global company engaged in various pharmaceutical sectors including Radiopharma, Allergy Immunotherapy, and Contract Research Development and Manufacturing Organisation (CRDMO). It operates through its subsidiary Jubilant Pharma Limited, which is involved in manufacturing and supplying radiopharmaceuticals, allergy immunotherapy products, and sterile injectables. The company has a significant presence in regulated markets such as the USA and Europe, and is recognized as a ‘Partner of Choice’ by leading pharmaceutical companies worldwide.
Average Trading Volume: 11,619
Technical Sentiment Signal: Buy
Current Market Cap: 175.8B INR
See more data about JUBLPHARMA stock on TipRanks’ Stock Analysis page.